Enhancing treatment for glioblastoma by targeting tumor inflammation
Improving Glioma Immunotherapy Efficacy by Regulating Tumor Inflammation
This study is looking at a new way to make immunotherapy work better for people with glioblastoma, a tough type of brain cancer, by blocking a specific receptor that helps the tumor grow, and patients may have the chance to participate in trials testing this promising approach.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beckman Research Institute/city of Hope NIH-funded |
| Lab location | 1 site (Duarte, United States) |
| Project ID | NIH-10912015 on NIH RePORTER |
What this research studies
This research investigates how to improve the effectiveness of immunotherapy for glioblastoma, a type of brain cancer known for its aggressive nature and poor survival rates. The approach focuses on inhibiting a specific receptor, RAGE, which is involved in promoting tumor growth and resistance to treatment. By targeting RAGE, the researchers aim to create a more favorable environment for immunotherapy to work effectively against glioblastoma. Patients may be involved in trials that explore this innovative treatment strategy.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with glioblastoma who have not responded well to standard therapies.
Not a fit: Patients with other types of brain tumors or those who are not diagnosed with glioblastoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve survival rates and treatment outcomes for patients with glioblastoma.
How similar studies have performed: Previous research has shown promising results in targeting similar pathways for enhancing immunotherapy efficacy in cancer treatment.
Where this research is happening
Duarte, United States
- Beckman Research Institute/city of Hope — Duarte, United States (Active)
Researchers
- Principal investigator: Badie, Behnam — Beckman Research Institute/city of Hope
- Study coordinator: Badie, Behnam
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.